AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Oramed Pharmaceuticals Inc. Director's Dealing 2022

May 3, 2022

6965_dirs_2022-05-03_219ba00f-a7fb-4226-9c0e-631a8467e261.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2022-05-02

Reporting Person: Rozov Yadin (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-05-02	Common Stock	A	4500	—	Acquired	4500	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-05-02	Stock Option (right to buy)	$5.14	A	7500	Acquired	2032-05-02	Common Stock (7500)	Direct

Footnotes

F1: Represents Restricted Stock Units ("RSUs") that will vest in 4 installments as follows: 1,125 shall vest on each of May 2, 2023, May 2, 2024, May 2, 2025 and May 2, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.

F2: The Stock Option will vest in 4 installments as follows: 1,875 shall vest on each of May 2, 2023, May 2, 2024, May 2, 2025 and May 2, 2026.